Kilambi News
Sunday, November 22, 2026

Archive

Every story, newest first.

Thursday, October 29, 2026

Life Sciences

Viking widens loss as four VK2735 Phase 3 trials run

Viking Therapeutics reported a third quarter net loss of $183.2 million, or $1.55 per share, on October 28, as it started the SUNRISE Phase 3 program for oral VK2735 alongside its two subcutaneous VANQUISH trials, ending the quarter with $960 million in cash and investments.

Life Sciences

Takeda raises full year forecast after first half profit jumps

Takeda reported first half fiscal 2026 revenue of 2,407.0 billion yen, up 8.4 percent at actual exchange rates, with net profit of 305.6 billion yen, and raised its full year revenue forecast to 4,700.0 billion yen from 4,640.0 billion yen on October 29.

Life Sciences

Life sciences also notable: BioGeometry raise, Flagship Etcelera launch

Beijing based BioGeometry closed a Series A extension taking its Series A total above $100 million, and Flagship Pioneering merged three portfolio companies into Etcelera Therapeutics, leading the smaller life sciences items for October 29.

Life Sciences

LENZ chief executive steps down as VIZZ sales rise 50 percent

LENZ Therapeutics said on October 28 that third quarter sales of VIZZ, its presbyopia eye drop, rose about 50 percent over the second quarter to $2.6 million on more than 38,000 paid prescriptions, and that chief executive Eef Schimmelpennink will step down on December 1, 2026.

Life Sciences

Glaukos revenue jumps 58 percent and guidance rises sharply

Glaukos reported record third quarter net sales of $211.0 million, up 58 percent, on October 28, and raised full year 2026 guidance to $775 million to $785 million, from $680 million to $700 million, with preliminary 2027 sales guidance of $1 billion.

Life Sciences

Genmab petosemtamab combination halves death risk in head neck cancer

Genmab said on October 28 that petosemtamab plus pembrolizumab met both primary endpoints at the first interim analysis of the Phase 3 LiGeR-HN1 trial, reducing the risk of death by 50 percent against pembrolizumab alone in first line PD-L1 positive recurrent or metastatic head and neck cancer.

Life Sciences

Formation Bio launches $600 million fund for stalled drug candidates

Formation Bio announced on October 28 a $600 million debut fund, the Formation Bio Drug Development Accelerator Fund, to acquire or license stalled clinical stage drug candidates and advance them with its AI native development platform.

Life Sciences

FDA grants Hutchmed sovleplenib orphan drug designation for ITP

Hutchmed said on October 29 that the Food and Drug Administration has granted Orphan Drug Designation to sovleplenib, its oral Syk inhibitor, for primary immune thrombocytopenia, making it eligible for seven years of United States market exclusivity if approved.

Rates

Bank of England opens tokenised collateral route for clearing

The Bank of England launched a consultation on October 29 supporting central counterparties to accept tokenised forms of eligible collateral, saying its existing framework is not a barrier provided the collateral can be valued, transferred and realised in stressed conditions.

Rates

Bank of Canada hikes to 2.50 percent, warns of pass-through

The Bank of Canada raised its overnight rate target by 25 basis points to 2.50 percent on October 28, its first increase since 2023, saying CPI inflation near 3 percent since April could reach about 3.5 percent by year end.